Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Editas Medicine stock | 29.06

Own Editas Medicine stock in just a few minutes.


Fact checked

Editas Medicine, Inc is a biotechnology business based in the US. Editas Medicine shares (EDIT) are listed on the NASDAQ and all prices are listed in US Dollars. Editas Medicine employs 208 staff and has a trailing 12-month revenue of around USD$32.6 million.

How to buy shares in Editas Medicine

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Editas Medicine. Find the stock by name or ticker symbol: EDIT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Editas Medicine reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$29.06, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Editas Medicine, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Editas Medicine. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Editas Medicine's share price?

Since the stock market crash in March caused by coronavirus, Editas Medicine's share price has had significant positive movement.

Its last market close was USD$29.06, which is 14.90% up on its pre-crash value of USD$24.73 and 107.42% up on the lowest point reached during the March crash when the shares fell as low as USD$14.01.

If you had bought USD$1,000 worth of Editas Medicine shares at the start of February 2020, those shares would have been worth USD$721.52 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,070.86.

Editas Medicine share price

Use our graph to track the performance of EDIT stocks over time.

Editas Medicine shares at a glance

Information last updated 2020-10-20.
Latest market close USD$29.06
52-week range USD$14.01 - USD$39.96
50-day moving average USD$31.3786
200-day moving average USD$29.6862
Wall St. target price USD$41.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.138

Buy Editas Medicine shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Editas Medicine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Editas Medicine price performance over time

Historical closes compared with the close of $29.06 from 2020-11-16

1 week (2020-11-17) 1.08%
1 month (2020-10-27) -10.60%
3 months (2020-08-25) -17.02%
6 months (2020-05-23) N/A
1 year (2019-11-25) 6.92%
2 years (2018-11-23) 3.67%
3 years (2017-11-24) 12.64%
5 years (2015-11-23) N/A

Editas Medicine financials

Revenue TTM USD$32.6 million
Gross profit TTM USD$-76,367,000
Return on assets TTM -18.79%
Return on equity TTM -42.59%
Profit margin 0%
Book value $6.911
Market capitalisation USD$2.1 billion

TTM: trailing 12 months

Shorting Editas Medicine shares

There are currently 10.5 million Editas Medicine shares held short by investors – that's known as Editas Medicine's "short interest". This figure is 7.5% up from 9.7 million last month.

There are a few different ways that this level of interest in shorting Editas Medicine shares can be evaluated.

Editas Medicine's "short interest ratio" (SIR)

Editas Medicine's "short interest ratio" (SIR) is the quantity of Editas Medicine shares currently shorted divided by the average quantity of Editas Medicine shares traded daily (recently around 908467.64960971). Editas Medicine's SIR currently stands at 11.53. In other words for every 100,000 Editas Medicine shares traded daily on the market, roughly 11530 shares are currently held short.

However Editas Medicine's short interest can also be evaluated against the total number of Editas Medicine shares, or, against the total number of tradable Editas Medicine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Editas Medicine's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Editas Medicine shares in existence, roughly 170 shares are currently held short) or 0.1684% of the tradable shares (for every 100,000 tradable Editas Medicine shares, roughly 168 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Editas Medicine.

Find out more about how you can short Editas Medicine stock.

Editas Medicine share dividends

We're not expecting Editas Medicine to pay a dividend over the next 12 months.

Editas Medicine share price volatility

Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $14.01 up to $39.96. A popular way to gauge a stock's volatility is its "beta".

EDIT.US volatility(beta: 2.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 2.0786. This would suggest that Editas Medicine's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Editas Medicine overview

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site